CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation announced today the appointment of Taunia Markvicka as Chief Commercial Officer (CCO). Taunia joins PixarBio from Pacira Pharmaceuticals where she was Chief Commercial Officer responsible for US sales of post-op pain drug Exparel.
Taunia will report to Frank Reynolds, the company’s founder and Chief Executive Officer. Taunia is another important piece to the company’s growing leadership infrastructure, and in maintaining momentum toward commercialization of NeuroRelease, PixarBio’s non-opiate and non-addictive pain treatments with expected FDA approvals in 2018.
Taunia brings a wealth of hands-on commercial experience and extensive leadership skills to PixarBio Corporation. She was at Pacira Pharmaceuticals for the past seven years, most recently as their SVP, Chief Commercial Officer where she was responsible for all North American sales and marketing efforts for the global launch of Exparel, as well as, National Accounts, Sales Training, Analytics and Operations.
Taunia will develop and execute PixarBio Corporation’s overall Sales strategy while overseeing all product launches. She’ll be accountable for all facets of commercialization; market analysis, strategic planning, product roll-out and launch, sales forecasts, sales/marketing budgets, life cycle management, and maximizing cross functional teams.
Taunia is a proven leader who combines a MBA from Saint Joseph University & a Doctor of Pharmacy from the University of Nebraska Medical Center, with a total commitment to excellence, resulting in significant achievements in executive leadership, commercialization, sales and marketing. She brings excellent business acumen to the c-suite and has led cross-functional teams to successfully roll out the only FDA approved post-op pain treatment Exparel. She is recognized as a key influencer up, down and across her organizations, gaining buy-in and sponsorship for organization wide strategies and execution. Taunia lives in New Jersey with her husband, and two children and she will work out of the PixarBio-New York Office.
“Taunia is the perfect accelerator for our 2016-2018 projects. We’ve spent 2016 optimizing our 2017 clinical studies for knee, hip, and shoulder surgical post-op pain, and we remain confident for US FDA approval in 2018. 90% of OB/GYNs indicated they desire a non-opioid, non-addictive pain treatment, and ranked a 14 day post-op pain treatment for C-sections as optimal post-op pain treatment so we’ve added C-Section to our planned clinical studies in 2017" said PixarBio CEO Frank Reynolds.
About PixarBio Corporation
Cofounded by Frank Reynolds, MIT’s Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio is focused on R&D around targeted drug and cell delivery systems to treat pain, epilepsy, spinal cord injury, and Parkinson’s disease. For more information visit www.pixarbio.com.